Metalloproteases 2 and 9, Lp-PLA2 and Lipoprotein Profile in Coronary Patients

Archives of Medical Research

Volumn 40, Issue 1, 2009, Pages 48-53

  Muzzio, Maria Luz ^a   Miksztowicz, Veronica ^a   Brites, Fernando ^a   Aguilar, Daniel ^b   Repetto, Esteban Martin ^a   Wikinski, Regina ^a   Tavella, Marcelo ^b   Schreier, Laura ^a   Berg, Gabriela Alicia ^a  

^a University of Buenos Aires   (Argentina)

^b UNIVERSIDAD NACIONAL DE LA PLATA   (Argentina)

Author keywords

Lp PLA2, lipoproteins; Metalloproteases; Plaque vulnerability

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B; C REACTIVE PROTEIN; GELATINASE A; GELATINASE B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; ZYMOGRAPHY;

AGED; CORONARY DISEASE; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PHOSPHOLIPASES A2;

EID: 57049147483     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2008.10.011     Document Type: Article

References (29)

1. Glass C.K., and Witztum J.L. Atherosclerosis: the road ahead. Cell 104 (2001) 503-516
2. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 138 (1999) S419-S420
3. Libby P. Vascular biology of atherosclerosis: overview and state of the art. Am J Cardiol 91 (2003) 3A-6A
4. Johnson J.L. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 5 (2007) 265-282
5. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200 (2003) 448-464
6. Lijnen H.R. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 33 (2003) 275-281
7. Jong G.P., Ma T., Chou P., Chang M.H., Wu C.H., Lis P.C., et al. Serum MMP-9 activity as a diagnosing marker for the developing heart failure of post MI patients. Chin J Physiol 49 (2006) 104-109
8. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev 85 (2005) 1-31
9. Johnson J.L., George S.J., Newby A.C., and Jackson C.L. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 102 (2005) 15575-15580
10. Carpenter K.L., Dennis I.F., Challis I.R., Osborn D.P., Macphee C.H., Leake D.S., et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 505 (2001) 357-363
11. Zalewski A., and Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25 (2005) 923-931
12. Shi Y., Zhang P., Zhang L., Osman H., Mohler III E.R., Macphee C., et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 191 (2007) 54-62
13. Lee C., Lee J., Choi Y.A., Kang S.S., and Baek S.H. cAMP elevating agents suppress secretory phospholipase A(2)-induced matrix metalloproteinase-2 activation. Biochem Biophys Res Commun 340 (2006) 1278-1283
14. Gensini G.G. Coronary Arteriography (1995), Futura Publishing Co., New York
15. Steinmetz E.F., Buckley C., Shames M.L., Ennis T.L., Vanvickle-Chavez S.J., Mao D., et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 241 (2005) 92-101
16. Huang C.Y., Wu T.C., Lin W.T., Leu H.B., Lin C.P., Lin S.J., et al. Effects of simvastatin withdrawal on serum matrix metalloproteinases in hypercholesterolaemic patients. Eur J Clin Invest 36 (2006) 76-84
17. 2. Clin Chem 29 (1983) 2026-2030
18. Assmann G., Jabs H.U., Kohnert U., Nolte W., and Schriewer H. LDL-cholesterol determination in blood serum following precipitation of LDL with polyvinyl sulfate. Clin Chim Acta 140 (1984) 77-83
19. Kleiner D.E., and Stetler-Stevenson W.G. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218 (1994) 325-329
20. Blank M.L., Hall M.N., Cress E.A., and Snyder F. Inactivation of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine by a plasma acetylhydrolase: higher activities in hypertensive rats. Biochem Biophys Res Commun 113 (1983) 666-671
21. Muzzio M.L., Berg G., Zago V., Basilio F., Sanguinetti S., Lopez G., et al. Circulating small dense LDL, endothelial injuring factors and fibronectin in healthy postmenopausal women. Clin Chim Acta 381 (2007) 157-163
22. Newby A.C. Do metalloproteinases destabilize vulnerable atherosclerotic plaques?. Curr Opin Lipidol 17 (2006) 556-561
23. de Nooijer R., Verkleij C.J., von der Thüsen J.H., Jukema J.W., van der Wall E.E., van Berkel T.J., et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 26 (2006) 340-346
24. Blankenberg S., Rupprecht H.J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
25. Nanni S., Melandri G., Hanemaaijer R., Cervi V., Tomasi L., Altimari A., et al. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res 149 (2007) 137-144
26. Zeng B., Prasan A., Fung K.C., Solanki V., Bruce D., Freedman S.B., et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 35 (2005) 331-335
27. Altieri P., Brunelli C., Garibaldi S., Nicolino A., Ubaldi S., Spallarossa P., et al. Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33 (2003) 648-656
28. Singh U., Dasu M.R., Yancey P.G., Afify A., Devaraj S., and Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res 49 (2008) 1015-1023
29. Koenig W., Khuseyinova N., Löwel H., Trischler G., and Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110 (2004) 1903-1908